mazen animal health - watt global media · 11/26/2018 · mazen experienced leadership team animal...
TRANSCRIPT
Mazen Animal Health
Jennifer Filbey, Ph.D.
CEO
November 7, 2018
First in Class Edible Vaccines
Feed–Through Vaccines For Production Animals
Positive Disruption is our Mission
Producers need:• Increased biosecurity
• Increased production margins
• Decreased antibiotics usage
• Improved disease prevention
Key Unmet Needs in Production Animals
Mazen proposes:• Subunit vaccines (ARS)
• Cost effective
• Replaces antibiotics
• Efficacy demonstrated
Coccidiosis causes $3.5B in annual losses
Mazen & USDA-ARS are Joining Forces to Provide a Cost-
Effective Vaccine Solution to Coccidiosis
• Coccidiosis is currently managed using a cyclical approach of spray
or water-based live vaccines alternated with ionophore antibiotics
and other anti-coccidiosis measures
• We need a safer, more efficacious, easier to use and cost-effective
approach
ARS has sub-unit antigens shown to be
effective against Eimeria infections
• EF-1alpha
• 3-1e/profilin
• Gam82
Mazen can express sub-unit vaccines in
maize grain creating “edible” vaccines
• Can be dosed with feed
• Cost effective
• Can’t replicate
Lillehoj, H. S., Ding, X., Quiroz, M. A., Bevensee, E., and Lillehoj, E. P. (2005) Avian diseases 49, 112-117.
Lin, R.-Q., Lillehoj, H. S., Lee, S. K., Oh, S., Panebra, A., and Lillehoj, E. P. (2017) Veterinary parasitology 243, 79-84.
Jang, S. I., Lillehoj, H. S., Lee, S. H., Lee, K. W., Park, M. S., Cha, S.-R., Lillehoj, E. P., Subramanian, B. M., Sriraman, R., and Srinivasan, V. (2010) Vaccine 28, 2980-2985.
• Over 15 issued and pending patents• Process• Use• Enhanced immunogenicity• Promoters• Ex: 9,944,937
• Patents pending for PEDV and Valley Fever
• Strong IP estate in the U.S.
• Patents pending related to three antigens from USDA-ARS
Clear Defensible & Competitive Advantages
Global Vaccine Market is over $7BRevenue projected to reach $300M by 2026 with US & International
Sales
• Porcine Epidemic Diarrhea
Virus
• Valley fever
• Avian Coccidiosis
(50,000,000)
0
50,000,000
100,000,000
150,000,000
200,000,000
250,000,000
300,000,000
350,000,000
2020 2021 2022 2023 2024 2025 2026
Feline - Rabies
Canine -Rabies
Fish Vaccine -Trout
Feline -Panleuk, Calic,RhinoCanine -Parvo, Dist,HepFish Vaccine -Salmon
Poultry -Coccidiosis
PCV-2 -Swine/Piglet
PEDV -Swine/Piglet
Valley Fever -Canine
EBIT
Mazen Experienced Leadership TeamAnimal Health, Technical & Commercial Expertise
TEAM
Jenny Filbey,
PhD
Founder, CEO
CPA
CFO
John Howard,
PhD
Founder, CSO
Tom Overbay, DVM
Development
CPA
CFO
• World leader in protein
expression in maize grain
• CEO of ABI
• 30 years of biotech
experience
• Entrepreneur focused
on commercialization
of new technologies
• President of NPI
• Nektar, Nobex, Hoechst
• Regulatory, business
development, tech
operations
• Expedite Animal Health
• Finance & corporate
development
• Public & private
company experience
• Animal health, feed
ingredients & production
animal marketing
• Elanco
• Bayer
Candidate
Identified
Candidate
Identified
Kerryann
Kocher
Marketing
Experienced BoardAnimal Health, Technical & Commercial Expertise
TEAM
Kelly
Lechtenberg,
DVM
Terry Speizer,
MBARonan Molloy, JD
• President, Innovation
Stockyard
• Zoetis, Synbiotics,
Primus
• President of Midwest
Veterinary Services &
the Veterinary and
Biomedical Research
Center
• Infectious Disease
Model Specialist
• Food Animal
Production Consultant
• Serial entrepreneur
• Morro View Winery
• Domaine Alfred Winery
• Electec, Flextec
Jenny Filbey,
Ph.D.John Howard,
Ph.D.
• Entrepreneur focused
on commercialization
of new technologies
• President of NPI
• Nektar, Nobex,
Hoechst
• World leader in
protein expression in
maize grain
• CEO of ABI
• 30 years of biotech
experience
PoC Provides Value Creation
Implementation
Antigen
Production
PoC in
target
animal
Master Seed
Working
Seed
EfficacyPre-licensing
SerialsSafety
Key Risk Reduction Step
• Cost effective
• Safer to deliver
• More efficacious
• Global reach
Equity Financing Round is Open Targeting a $20M Raise
Fast to Market for First-in-Class Edible Vaccine
➢10+x multiple on
investment
➢Disrupt animal
disease prevention
globally
11
Jennifer Filbey, Ph.D.
CEO
+1-256-417-8568
www.mazenanimalhealth.com